DNA was extracted utilizing the
QIAamp Circulating Nucleic Acid Kit (Qiagen, Manchester, United Kingdom). ctDNA testing via dPCR assay was performed as previously described (2–10 (
link)). In brief, targeted-panel sequencing from two FFPE samples was performed using the ABC-Bio or RMH- 200 gene panels and one to two variants were selected for the dPCR assay (11, 12 ). The Thermo Scientific Custom TaqMan SNP Geneotyping Assay design tool was employed for assay design. Assay optimization was performed with a
ProFlex Thermal Cycler (Applied BioSystems),
Automated Droplet Generator (Bio-Rad, Pleasanton) and
Droplet Reader (Bio-Rad, Pleasanton). Two or more FAM-positive droplets were required for the sample to be called positive. If a positive result was obtained, this was independently confirmed on a second sample. Copies/mL and allele fraction were calculated as previously described (13 (
link)).
Coakley M., Villacampa G., Sritharan P., Swift C., Dunne K., Kilburn L., Goddard K., Pipinikas C., Rojas P., Emmett W., Hall P., Harper-Wynne C., Hickish T., Macpherson I., Okines A., Wardley A., Wheatley D., Waters S., Palmieri C., Winter M., Cutts R.J., Garcia-Murillas I., Bliss J, & Turner N.C. (2023). Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 30(4), 895-903.